3Eberlein A, von Kobyletzki G, Gruss C, et al. The successful monotherapy of hypereosinophilic dermatitis with PUVA-bath photochemotherapy Hautarzt 1997; 48:820-823.
4Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59:673-689.
5Prin L, Plumas J, Gruart V, et al. Elevated serum levels of soluble interleukin-2 receptor: a marker of disease activity in the hypereosinophilic syndromes. Blood 1991;79:2626-2632.
6Caixia T, Hongwen F, Xiran L. levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci 1999;21:59.
5Nir MA, Westfried M. Hypereosinophilic dermatitis. A distinct manifestation of the hypereosinophilic syndrome with response to dapsone[J]. Dermatologica, 1981, 162(6):444-450.
6Cogan E, Roufosse F. Clinical management of the hypereosinophilic syndromes [J]. Expert Rev Hematol, 2012, 5(3):275-289.
7Wechsler ME, Fulkerson PC, Bochner BS, et al. Novel targeted therapies for eosinophilic disorders[J]. J Allergy Clin Immunol, 2012,130(3):563-571.
8Odom RB, James WP, Berger TG. Andrews' Disease of the Skin [M]. 9th ed. Beijing: Science Press, 2001:940.
